Lynparza was given priority in the United States

MSD announced that it had successfully granted Lynparza (olaparib) a new application for a new drug and that it had been given priority review in combination with Genentech for advanced ovarian cancer.
The company said the priority review was based on the results of the key Phase III PAOLA-1 trial, which reduced the risk of disease progression or death by 41 percent on a 0.59 risk ratio and improved the median progression-free lifetime (PFS) to 22.1 months, compared with 16.6 months for beva monoantigen.
In addition, two years after the start of the trial, the double-blind Phase III trial found that 46 per cent of patients treated with the combination showed no progression, while 28 per cent of patients treated with beva monotherapy alone showed no progression.
State-of-the-art PARP inhibitors have also recently been approved in the United States as a first-line maintenance therapy for metastatic pancreatic cancer with BRCA mutations in the reproductive system, making it the first drug approved in pancreatic cancer. The drug is the third tumor type and fifth type of allergy in the United States.
Lynparza is being tested in a variety of PARP-dependent tumor types that are defective and dependent in the DDR pathway.
Ovarian cancer is the eighth leading cause of cancer death among women between the world, with nearly 300,000 new cases diagnosed and about 185,000 deaths diagnosed in 2018. Most women are diagnosed with advanced (Stage III or Stage IV) ovarian cancer and have a five-year survival rate of about 30%. （cyy123.com）